3,4-Methylenedioxymethamphetamine Self-Administration is Abolished in Serotonin Transporter Knockout Mice

Biological Psychiatry

Volumn 62, Issue 6, 2007, Pages 669-679

  Trigo, José Manuel ^a   Renoir, Thibault ^b   Lanfumey, Laurence ^b   Hamon, Michel ^b   Lesch, Klaus Peter ^d   Robledo, Patricia ^a,c   Maldonado, Rafael ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INSERM   (France)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

5 HT; DA; ecstasy; food and water operant responding; in vivo microdialysis; nucleus accumbens; prefrontal cortex

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SELF ADMINISTRATION; EXTRACELLULAR SPACE; GENOTYPE; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; TRAINING; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DOPAMINE; EXTRACELLULAR SPACE; HALLUCINOGENS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, KNOCKOUT; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; REINFORCEMENT (PSYCHOLOGY); REWARD; SELF ADMINISTRATION; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 34548149262     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.11.005     Document Type: Article

References (71)

1. Acquas E., Marrocu P., Pisanu A., Cadoni C., Zernig G., Saria A., et al. Intravenous administration of ecstasy (3,4-methylendioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418 (2001) 207-211
2. Auclair A., Blanc G., Glowinski J., and Tassin J.P. Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: Comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 91 (2004) 318-326
3. Auclair A., Drouin C., Cotecchia S., Glowinski J., and Tassin J.P. 5-HT2A and alpha1b-adrenergic receptors entirely mediate DA release, locomotor response and behavioral sensitization to opiates and psychostimulants. Eur J Neurosci 20 (2004) 3073-3084
4. Bankson M.G., and Yamamoto B.K. Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 91 (2004) 852-859
5. Beardsley P.M., Balster R.L., and Harris L.S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alcohol Depend 18 (1986) 149-157
6. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53 (1998) 649-655
7. Benloucif S., Keegan M.J., and Galloway M.P. Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 265 (1993) 373-377
8. Bilsky E.J., Hubbell C.L., Delconte J.D., and Reid L.D. MDMA produces a conditioned place preference and elicits ejaculation in male rats: A modulatory role for the endogenous opioids. Pharmacol Biochem Behav 40 (1991) 443-447
9. Bilsky E.J., Montegut M.J., Nichols M.L., and Reid L.D. CGS 10746B, a novel dopamine release inhibitor, blocks the establishment of cocaine and MDMA conditioned place preferences. Pharmacol Biochem Behav 59 (1998) 215-220
10. Bilsky E.J., and Reid L.D. MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol Biochem Behav 39 (1991) 509-512
11. Blandina P., Goldfarb J., Craddock-Royal B., and Green J.P. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 251 (1989) 803-809
12. Cadoni C., Solinas M., Pisanu A., Zernig G., Acquas E., and Di Chiara G. Effect of 3,4-methylendioxymethamphetamine (MDMA, "ecstasy") on dopamine transmission in the nucleus accumbens shell and core. Brain Res 1055 (2005) 143-148
13. Callaway C.W., Wing L.L., and Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254 (1990) 456-464
14. Camarero J., Sanchez V., O'Shea E., Green A.R., and Colado M.I. Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81 (2002) 961-972
15. Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., et al. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): Psychomotor performance and subjective effects. J Clin Psychopharmacol 20 (2000) 455-466
16. Carta M., Collu M., Fadda F., and Stancampiano R. Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet. Neurosci Lett 401 1-2 (2006) 125-129
17. Cottler L.B., Womack S.B., Compton W.M., and Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Hum Psychopharmacol 16 (2001) 599-606
18. Daniela E., Brennan K., Gittings D., Hely L., and Schenk S. Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol Biochem Behav 77 (2004) 745-750
19. David V., Gold L.H., Koob G.F., and Cazala P. Anxiogenic-like effects limit rewarding effects of cocaine in balb/cbyj mice. Neuropsychopharmacology 24 (2001) 300-318
20. Elmer G.I., Meisch R.A., and George F.R. Mouse strain differences in operant self-administration of ethanol. Behav Genet 17 (1987) 439-451
21. Fabre V., Beaufour C., Evrard A., Rioux A., Hanoun N., Lesch K.P., et al. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 12 (2000) 2299-2310
22. Fantegrossi W.E., Kiessel C.L., De la Garza II R., and Woods J.H. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl) 181 (2005) 529-536
23. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., and Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: Serotoninergic involvement. Psychopharmacology (Berl) 161 (2002) 356-364
24. Ferré S., and Artigas F. Dopamine D2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem 61 (1993) 772-775
25. Ferré S., Cortes R., and Artigas F. Dopaminergic regulation of the serotonergic raphe-striatal pathway: Microdialysis studies in freely moving rats. J Neurosci 14 (1994) 4839-4846
26. Foltin R.W. Effects of dietary and pharmacological manipulations on appetitive and consummatory aspects of feeding in non-human primates. Appetite 45 (2005) 110-120
27. Foltin R.W. Effects of sibutramine on the appetitive and consummatory aspects of feeding in non-human primates. Physiol Behav 87 (2006) 280-286
28. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
29. Gainetdinov R.R., and Caron M.G. Monoamine transporters: From genes to behavior. Annu Rev Pharmacol Toxicol 43 (2003) 261-284
30. Goodwin A.K., Pynnonen D.M., and Baker L.E. Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74 (2003) 987-995
31. Grahame N.J., and Cunningham C.L. Genetic differences in intravenous cocaine self-administration between C57BL/6J and DBA/2J mice. Psychopharmacology (Berl) 122 (1995) 281-291
32. Green A.R., Cross A.J., and Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 119 (1995) 247-260
33. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6 (2006) 6
34. Hekmatpanah C.R., and Peroutka S.J. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177 (1990) 95-98
35. Holmes A., Lit Q., Murphy D.L., Gold E., and Crawley J.N. Abnormal anxiety-related behavior in serotonin transporter null mutant mice: The influence of genetic background. Genes Brain Behav 2 (2003) 365-380
36. Holmes A., Murphy D.L., and Crawley J.N. Abnormal behavioral phenotypes of serotonin transporter knockout mice: Parallels with human anxiety and depression. Biol Psychiatry 54 (2003) 953-959
37. Holmes A., Yang R.J., Lesch K.P., Crawley J.N., and Murphy D.L. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28 (2003) 2077-2088
38. Kelaï S., Aissi F., Lesch K.P., Cohen-Salmon C., Hamon M., and Lanfumey L. Alcohol intake after serotonin transporter inactivation in mice. Alcohol Alcohol 38 (2003) 386-389
39. Koch S., and Galloway M.P. MDMA induced dopamine release in vivo: Role of endogenous serotonin. J Neural Transm 104 (1997) 135-146
40. Lamb R.J., and Griffiths R.R. Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 91 (1987) 268-272
41. LeSage M.G., Stafford D., and Glowa J.R. Effects of anorectic drugs on food intake under progressive-ratio and free-access conditions in rats. J Exp Anal Behav 82 (2004) 275-292
42. Li Q., Wichems C.H., Ma L., Van de Kar L.D., Garcia F., and Murphy D.L. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 84 (2003) 1256-1265
43. Liechti M.E., Baumann C., Gamma A., and Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22 (2000) 513-521
44. Liechti M.E., Saur M.R., Gamma A., Hell D., and Vollenweider F.X. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 (2000) 396-404
45. Lile J.A., Ross J.T., and Nader M.A. A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys. Drug Alcohol Depend 78 (2005) 135-140
46. Marona-Lewicka D., Rhee G.S., Sprague J.E., and Nichols D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 53 (1996) 99-105
47. Mathews T.A., Fedele D.E., Coppelli F.M., Avila A.M., Murphy D.L., and Andrews A.M. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140 (2004) 169-181
48. Murphy P.N., Wareing M., and Fisk J. Users' perceptions of the risks and effects of taking ecstasy (MDMA): A questionnaire study. J Psychopharmacol 20 (2006) 447-455
49. Piasecki M.P., Steinagel G.M., Thienhaus O.J., and Kohlenberg B.S. An exploratory study: The use of paroxetine for methamphetamine craving. J Psychoactive Drugs 34 (2002) 301-304
50. Ratzenboeck E., Saria A., Kriechbaum N., and Zernig G. Reinforcing effects of MDMA ("ecstasy") in drug-naive and cocaine-trained rats. Pharmacology 62 (2001) 138-144
51. Rioux A., Fabre V., Lesch K.P., Moessner R., Murphy D.L., Lanfumey L., et al. Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett 262 (1999) 113-116
52. Robledo P., Balerio G., Berrendero F., and Maldonado R. Study of the behavioral responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 338-349
53. Robledo P., Mendizabal V., Ortuno J., de la Torre R., Kieffer B.L., and Maldonado R. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur J Neurosci 20 (2004) 853-858
54. Rocha B.A. Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol 479 (2003) 107-115
55. Rocha B.A., Odom L.A., Barron B.A., Ator R., Wild S.A., and Forster M.J. Differential responsiveness to cocaine in C57BL/6J and DBA/2J mice. Psychopharmacology (Berl) 138 (1998) 82-88
56. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479 (2003) 23-40
57. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
58. Salzmann J., Marie-Claire C., Le Guen S., Roques B.P., and Noble F. Importance of ERK activation in behavioral and biochemical effects induced by MDMA in mice. Br J Pharmacol 140 (2003) 831-838
59. Scearce-Levie K., Viswanathan S.S., and Hen R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl) 141 (1999) 154-161
60. Schechter M.D. Drug-drug discrimination: Stimulus properties of drugs of abuse upon a serotonergic-dopaminergic continuum. Pharmacol Biochem Behav 56 (1997) 89-96
61. Schenk S., Gittings D., Johnstone M., and Daniela E. Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rat. Psychopharmacology (Berl) 169 (2003) 21-27
62. Schmidt C.J., Levin J.A., and Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36 (1987) 747-755
63. Schmidt C.J., Sullivan C.K., and Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62 (1994) 1382-1389
64. Shen H.W., Hagino Y., Kobayashi H., Shinohara-Tanaka K., Ikeda K., Yamamoto H., et al. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29 (2004) 1790-1799
65. Sora I., Hall F.S., Andrews A.M., Itokawa M., Li X.F., Wei H.B., et al. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A 98 (2001) 5300-5305
66. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Revay R., et al. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A 95 (1998) 7699-7704
67. Soria G., Mendizabal V., Tourino C., Robledo P., Ledent C., Parmentier M., et al. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30 (2005) 1670-1680
68. Thomsen M., and Caine S.B. Cocaine self-administration under fixed and progressive ratio schedules of reinforcement: Comparison of C57BL/6J, 129X1/SvJ, and 129S6/SvEvTac inbred mice. Psychopharmacology (Berl) 184 (2006) 145-154
69. Trigo J.M., Panayi F., Soria G., Maldonado R., and Robledo P. A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology (Berl) 184 (2006) 212-220
70. White S.R., Obradovic T., Imel K.M., and Wheaton M.J. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49 (1996) 455-479
71. Yamamoto B.K., and Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148 (1988) 195-203